356 related articles for article (PubMed ID: 23659787)
1. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.
Davie BJ; Christopoulos A; Scammells PJ
ACS Chem Neurosci; 2013 Jul; 4(7):1026-48. PubMed ID: 23659787
[TBL] [Abstract][Full Text] [Related]
2. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa M; Hesse S; Bradley SJ
Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
[TBL] [Abstract][Full Text] [Related]
3. Bitopic Binding Mode of an M
Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
[TBL] [Abstract][Full Text] [Related]
4. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW
Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397
[TBL] [Abstract][Full Text] [Related]
5. Positive allosteric modulation of M
Yohn SE; Conn PJ
Neuropharmacology; 2018 Jul; 136(Pt C):438-448. PubMed ID: 28893562
[TBL] [Abstract][Full Text] [Related]
6. Opportunities and challenges for the development of M
Nguyen HTM; van der Westhuizen ET; Langmead CJ; Tobin AB; Sexton PM; Christopoulos A; Valant C
Br J Pharmacol; 2024 Jul; 181(14):2114-2142. PubMed ID: 36355830
[TBL] [Abstract][Full Text] [Related]
7. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.
Bradley SJ; Bourgognon JM; Sanger HE; Verity N; Mogg AJ; White DJ; Butcher AJ; Moreno JA; Molloy C; Macedo-Hatch T; Edwards JM; Wess J; Pawlak R; Read DJ; Sexton PM; Broad LM; Steinert JR; Mallucci GR; Christopoulos A; Felder CC; Tobin AB
J Clin Invest; 2017 Feb; 127(2):487-499. PubMed ID: 27991860
[TBL] [Abstract][Full Text] [Related]
8. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
Conn PJ; Jones CK; Lindsley CW
Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M
van der Westhuizen ET; Spathis A; Khajehali E; Jörg M; Mistry SN; Capuano B; Tobin AB; Sexton PM; Scammells PJ; Valant C; Christopoulos A
Mol Pharmacol; 2018 Jul; 94(1):770-783. PubMed ID: 29691279
[TBL] [Abstract][Full Text] [Related]
10. Structural Features of Iperoxo-BQCA Muscarinic Acetylcholine Receptor Hybrid Ligands Determining Subtype Selectivity and Efficacy.
Wakeham MCL; Davie BJ; Chalmers DK; Christopoulos A; Capuano B; Valant C; Scammells PJ
ACS Chem Neurosci; 2022 Jan; 13(1):97-111. PubMed ID: 34905693
[TBL] [Abstract][Full Text] [Related]
11. 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor.
Mistry SN; Jörg M; Lim H; Vinh NB; Sexton PM; Capuano B; Christopoulos A; Lane JR; Scammells PJ
J Med Chem; 2016 Jan; 59(1):388-409. PubMed ID: 26624844
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
[TBL] [Abstract][Full Text] [Related]
13. 6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M
Jörg M; van der Westhuizen ET; Khajehali E; Burger WAC; White JM; Choy KHC; Tobin AB; Sexton PM; Valant C; Capuano B; Christopoulos A; Scammells PJ
ACS Chem Neurosci; 2019 Mar; 10(3):1099-1114. PubMed ID: 30547573
[TBL] [Abstract][Full Text] [Related]
14. M1 muscarinic acetylcholine receptor in Alzheimer's disease.
Jiang S; Li Y; Zhang C; Zhao Y; Bu G; Xu H; Zhang YW
Neurosci Bull; 2014 Apr; 30(2):295-307. PubMed ID: 24590577
[TBL] [Abstract][Full Text] [Related]
15. M
Hassani SA; Neumann A; Russell J; Jones CK; Womelsdorf T
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2216792120. PubMed ID: 37104474
[TBL] [Abstract][Full Text] [Related]
16. A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice.
Abd-Elrahman KS; Sarasija S; Colson TL; Ferguson SSG
Br J Pharmacol; 2022 Apr; 179(8):1769-1783. PubMed ID: 34820835
[TBL] [Abstract][Full Text] [Related]
17. Role of Conserved Tyrosine Lid Residues in the Activation of the M
Pham V; Habben Jansen MCC; Thompson G; Heitman LH; Christopoulos A; Thal DM; Valant C
Mol Pharmacol; 2023 Sep; 104(3):92-104. PubMed ID: 37348914
[TBL] [Abstract][Full Text] [Related]
18. M
Fu L; Luo Y; Niu L; Lin Y; Chen X; Zhang J; Tang W; Chen Y; Jiao Y
Bioorg Med Chem; 2024 May; 105():117728. PubMed ID: 38640587
[TBL] [Abstract][Full Text] [Related]
19. Muscarinic receptor pharmacology and circuitry for the modulation of cognition.
Bubser M; Byun N; Wood MR; Jones CK
Handb Exp Pharmacol; 2012; (208):121-66. PubMed ID: 22222698
[TBL] [Abstract][Full Text] [Related]
20. Diverse Effects on M
Rook JM; Abe M; Cho HP; Nance KD; Luscombe VB; Adams JJ; Dickerson JW; Remke DH; Garcia-Barrantes PM; Engers DW; Engers JL; Chang S; Foster JJ; Blobaum AL; Niswender CM; Jones CK; Conn PJ; Lindsley CW
ACS Chem Neurosci; 2017 Apr; 8(4):866-883. PubMed ID: 28001356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]